212 related articles for article (PubMed ID: 25234021)
1. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC.
Medina Fernández FJ; Muñoz-Casares FC; Arjona-Sánchez A; Casado-Adam A; Gómez-Luque I; Garcilazo Arismendi DJ; Thoelecke H; Rufián Peña S; Briceño Delgado J
Ann Surg Oncol; 2015 Apr; 22(4):1332-40. PubMed ID: 25234021
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.
Leimkühler M; Hemmer PHJ; Reyners AKL; de Groot DJA; van Ginkel RJ; Been LB; de Bock GH; van Leeuwen BL
World J Surg Oncol; 2019 Jan; 17(1):14. PubMed ID: 30635070
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
6. Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study.
Maillet M; Glehen O; Lambert J; Goere D; Pocard M; Msika S; Passot G; Elias D; Eveno C; Sabaté JM; Lourenco N; André T; Gornet JM;
Ann Surg Oncol; 2016 Mar; 23(3):863-9. PubMed ID: 26480848
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
9. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status.
Ihemelandu CU; McQuellon R; Shen P; Stewart JH; Votanopoulos K; Levine EA
Ann Surg Oncol; 2013 Oct; 20(11):3519-26. PubMed ID: 23748607
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial.
Liu Y; Endo Y; Fujita T; Ishibashi H; Nishioka T; Canbay E; Li Y; Ogura S; Yonemura Y
Ann Surg Oncol; 2014 Dec; 21(13):4256-62. PubMed ID: 25056850
[TBL] [Abstract][Full Text] [Related]
11. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
12. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
13. Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience.
Deraco M; Sinukumar S; Salcedo-Hernández RA; Rajendra VJ; Baratti D; Guaglio M; Nizri E; Kusamura S
Eur J Surg Oncol; 2019 Nov; 45(11):2103-2108. PubMed ID: 31230982
[TBL] [Abstract][Full Text] [Related]
14. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J
Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037
[TBL] [Abstract][Full Text] [Related]
15. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
Bhagwandin SB; Naffouje S; Salti G
J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
Cascales Campos P; Gil J; Parrilla P
Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
[TBL] [Abstract][Full Text] [Related]
18. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH
Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammatory markers for the detection of infectious complications and safe discharge after cytoreductive surgery and HIPEC.
Viyuela García C; Medina Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez Hidalgo JM; Rufián Peña S; Briceño Delgado J
Surg Oncol; 2020 Sep; 34():163-167. PubMed ID: 32891323
[TBL] [Abstract][Full Text] [Related]
20. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
